Key facts
- It has raised $110K; the latest was Angel (individual) ($110K) in Mar 2026.
- AlloDirect has filed 1 Form D with the SEC, most recently Mar 2026 ($110K sold to 5 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for AlloDirect
- ·The full record, as it builds
Funding rounds
No funding rounds for AlloDirect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AlloDirect
Developer of a procurement platform intended to connect ASCs to tissue banks. The company's platform ensures that every donated tissue reaches the right surgeon, for the right patient, at the right time, through real-time inventory visibility, AI-powered demand forecasting, one-click audit reporting, and cost optimization, enabling users to obtain a clear and predictable biological supply and direct connections to accredited tissue banks and outpatient surgery centers.
- Sector
- Information Technology
- HQ
- Valparaiso, IN, United States
- Founded
- 2024
- Website
- allo.direct/
- Ownership
- Privately Held (backing)
AlloDirect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AlloDirect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AlloDirect in its N-PORT filings yet. We sweep new filings monthly.